In retinoblastoma research tumor-derived cell lines remain an important model to investigate tumorigenesis and new therapy options, due to limited tumor material and lack of adequate animal models. A panel of 10 retinoblastoma cell lines was characterized with respect to mutation, methylation and expression of RB1 and MYCN. These established retinoblastoma cell lines represent the most frequent types of RB1 inactivation and together with the MYCN amplification status, three classes can be distinguished:
Introduction
Retinoblastoma is the most common tumor of the eye in childhood. The worldwide incidence is about one case per 15,000-20,000 live births [15] . The tumor arises from immature retinal cells and is usually characterized by biallelic loss of the tumor suppressor gene retinoblastoma gene 1 (RB1) [8, 22, 49] . However, some retinoblastoma do not show inactivation of the RB1 gene, but an amplification of the MYCN gene (RB1 wt /MYCN A ) [35] . Amplification of MYCN is long known as predictive risk factor in pediatric neuroblastoma, where it is associated with aggressive disease and poor outcome [3] . The patients suffering from RB1 wt /MYCN A retinoblastoma were reported to be especially young at diagnosis, with a median age of 4.5 months and to show large and invasive tumors [35] . The tumors were characterized by undifferentiated histology and resembled MYCN amplified neuroblastoma [35] .
Generally, patients with retinoblastoma have excellent curing prospects but they often suffer from long-term side effects including loss of vision and second primary malignancies [43, 44] . Metastatic disease is rare and mainly observed in patients from developing countries, but these cases still pose a challenge for pediatric oncologists [7, 29] . It is necessary to develop new therapeutic strategies in order to reduce longterm sequelae and to improve the survival chances of metastatic patients.
A model system to investigate tumorigenesis and to develop new therapy approaches is therefore indispensable. Up to now an adequate animal model is not available. The spontaneous generation of retinoblastoma seems to be limited to humans and mimicking its structural and functional properties in mice is difficult [28, 42] . Patient-derived xenograft models, in which patient-derived tumor cells are injected into the eye of immunocompromised mice or rats, facilitate monitoring of tumor development, migration and invasiveness and allow to elaborate possible treatment options [31, 32, 46] . But with eye-preserving therapy of retinoblastoma tumor material will become less available [21] . Established retinoblastoma cell line models, which provide unlimited amount of material, provide an invaluable tool for in vitro research on this disease. Already today, in vitro assays employing retinoblastoma cell lines are used to investigate tumorigenesis and treatment strategies [4, 36, 39] . For example, treatment of retinoblastoma cell lines with PLK1 inhibitors (BI2353 and GSK461364) resulted in enhanced apoptosis, reduced proliferation and activation of the TP53 pathway [39] . An example for a successful bench-to-bedside transfer is the suggestion to combine topotecan with vincristine and carboplatin as new frontline therapy in retinoblastoma. This treatment regimen was first tested in preclinical studies in retinoblastoma cell lines and orthotopic xenograft animal models and recently proofed to be effective in eye and vision preservation in patients [2, 18, 30] . Retinoblastoma cell lines, Y79, WERI-Rb1 and RB355, have been used in high-throughput screenings for identification of compounds with anti-proliferative capacity [1, 24] . This demonstrates the versatility and value of retinoblastoma cell lines in pre-clinical testing. To date, 105 human retinoblastoma cell lines have been established from tumor samples of different patients (Supplementary table 1) . For an accurate evaluation of research results, a detailed characterization of these cell lines is mandatory. Characterization of singular cell lines have been published before, mainly describing growth and proliferation patterns or migration capabilities [5] .
To strengthen the basis of retinoblastoma cell lines for in vitro research and as pre-clinical models, in depth characterization of 10 retinoblastoma cell lines regarding the RB1 and MYCN status and presence of mutations in tumor-associated genes other than RB1 were conducted. The selected cell lines represented the main genetic and epigenetic RB1 retinoblastoma causing alterations, including the presence of MYCN amplification without RB1 mutation in the newly established cell lines RB522 and RB3823. According to these criteria, cell lines were assigned to one of the following groups: RB1 mut /MYCN nonA ,
RB1
mut /MYCN A and RB1 wt /MYCN A . Please note that in this context RB1 mut includes all genetic and epigenetic changes to RB1. The impact of RB1 mutation and MYCN amplification status on expression of key regulatory genes in cell cycle and apoptosis control was determined.
Only such well characterized retinoblastoma-derived cell lines can serve as valid models for retinoblastoma biology.
Materials and methods

Cell lines
Cell lines RB247C3, RB355, RB383, RB522 and RB3823 were kindly provided by Brenda Gallie (Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Ontario, Canada; [41] ). RBL13, RBL15 and RBL30 cell lines were established at the University Hospital Essen and were obtained from the Institute of Cell Biology, University Hospital Essen [13] . Cell lines, Y79 (DSMZ-ACC 246) and WERI-Rb1 (DSMZ-ACC 90), were purchased from the German collection of microorganisms and cell cultures. The human juvenile foreskin fibroblast cell line NHDF was purchased from PromoCell (catalog number C-12300). Human adult retina was obtained from eyes used for cornea donation at the Department of Ophthalmology at the University Hospital Essen.
Cell culture
Cell lines were cultivated in suspension in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen), 100 U/ml penicillin/streptomycin (Invitrogen) and 2.5 mg/l amphotericin B (PAA Laboratories GmbH) in a humidified atmosphere of 5% CO 2 at 37°C. RB355 and NHDF-C cells were cultivated as monolayer.
Gene expression analyses
RNA was isolated using the High Pure RNA Isolation Kit (Roche), and cDNA was synthesized from 500 ng total RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time PCR was performed with a 1:20 dilution of cDNA using FastStart Universal SYBR green master mix (Rox) (Roche). RB1 expression was measured using primer / probe assays based on the universal probe library and chemistry for the Roche LightCycler 480. Target gene expression was calculated using the ΔΔCt method with GAPDH as internal reference [37] . Primer sequences are provided in Supplementary table 7.
Western blot
Western blot was performed according to standard procedures. Cells (1 × 10 6 ) were lysed in 100 µl of NP40-buffer (500 mM NaCl, 20 mM Tris pH 8, 1 mM EDTA pH 8, 0.5% NP-40) supplemented with Halt Protease Inhibitor Cocktail (Thermo Fisher). Proteins were separated on 10% SDS polyacrylamide gels and transferred to nitrocellulose membrane (GE Healthcare). Antibodies used were RB1 (BD Pharmingen #554136, dilution 1:250), MYCN (Santa Cruz sc-53993, dilution 1:1000), GAPDH (Milipore MAB374, dilution 1:1000).
Multiplex ligation dependent probe amplification (MLPA)
MLPA using the SALSA MLPA probemix, P047-D1 RB1 (MRC Holland) was used to determine ploidy of target sequences and to detect small deletions and duplications within genes. Reactions were set up according to manufacturer's instructions. Fragment length analysis was performed on an ABI 3130XL Genetic Analyzer in reference to GeneScan 500 LIZ size standard and analyzed with GeneMarker software (SoftGenetics).
Sanger sequencing
Genomic DNA was isolated using the FlexiGene DNA kit (Qiagen) with following modifications: Resuspension of cells was conducted in 1 ml buffer FG1 followed by a 15 min incubation at room temperature on a roller mixer. Supernatant was discarded after centrifugation (3000 g, 10 min). After adding 500 µl buffer FG2 supplemented with protease samples were incubated at 56°C for 10 min. DNA precipitation, washing and solubilization was done according to manufacturer's recommendations. For sequencing, genomic DNA (100 ng/µl) was amplified by PCR using exon-specific primer combinations. For amplification of RB1 exon 1, the GC melt kit (Clontech Laboratories, California, CA, USA) was used. Reactions were run on an ABI 3130XL genetic analyzer and sequences were analyzed using the programs Sequencing Analysis (Applied Biosystems, Thermo Fisher Scientific) and Geneious (Biomatters). Primer sequences are listed in Supplementary Table 7.
Next-generation bisulfite amplicon sequencing
The EZ-DNA Methylation-Gold kit (Zymo Research) was used for bisulfite conversion of 500 ng genomic DNA for next generation bisulfite amplicon sequencing on the Roche Junior 450 platform as described [42] . Results were analyzed using the Amplikyzer program [34] . Primer sequences are provided in Supplementary table 7. 
Cancer panel targeted sequencing
Results
The genetic status of RB1 in all ten retinoblastoma cell lines was determined and re-evaluated by sequencing of single exons, multiplexligation dependent probe-amplification (MLPA) and microsatellite analysis (Table 1) . Single nucleotide exchanges and smaller deletions/ insertions were identified by sequencing, whereas MLPA was used to determine gene dosage and the presence of exon deletions.
Microsatellite analysis was employed to establish genetic markers for cell line identity testing (Supplementary table 2) and to conclude on zygosity state of chromosome 13. A complete deletion of the RB1 gene was identified in cell lines RBL15 and WERI-Rb1 by MLPA. The microsatellite analysis for RBL15 and WERI-Rb1 showed the presence of only one marker set for chromosome 13, indicative for loss of one chromosome (loss of heterozygosity, LOH). Cell lines RBL13, RB247C3, RB355 and Y79, harbor different mutations on both alleles in the RB1 gene. In line with this finding, gene dosage in MLPA was normal and microsatellite analysis showed presence of the two parental chromosomes 13. Cell lines RBL13, RBL247C3 and RB355, showed single nucleotide point mutations in different exons of the RB1 gene (Table 1 ). In the cell line Y79 a deletion of exons 2-6 on one allele and a splice donor site mutation of exon 20 on the other allele were detected by MLPA and sequencing. RBL30 cells carried a single nucleotide exchange (C to T) in exon 8 of the RB1 gene. MLPA showed normal gene dosage, indicative for presence of two alleles. However, microsatellite analysis revealed the presence of only one marker set, indicative for duplication of the mutant chromosome and therefore LOH. In cell lines, RB522, RB383 and RB3823, no mutations in any of the 27 exons of RB1 could be identified. RB522 and RB3823 cells displayed normal gene dosage in MLPA and presence of two parental chromosomes 13 by microsatellite analysis. Therefore, RB522 and RB3823 cells are wildtype in respect to the genetic status of RB1. RB383 cells showed a gene dosage of 1.5 in MLPA for all probes located on chromosome 13 indicating the presence of three chromosomes 13. Only one microsatellite marker set was called suggesting a triplication of chromosome 13 and LOH. RB1 can also be inactivated by hypermethylation of its promoter that is part of CpG island 106 [12] . DNA methylation at nine CpGs in CpG106 was determined by next-generation bisulfite amplicon sequencing (Fig. 1 ). RBL15 and WERI-Rb1 cells were not analyzed, since they showed a complete loss of RB1. In all cell lines, except RB383, the RB1 promoter CpG106 is free of methylation. In RB383 cells, the RB1 promoter showed hypermethylation to a level of 88.6%.
It has been demonstrated that high MYCN levels are beneficial for The table summarizes the results of sequencing, MLPA and microsatellite analyses of 10 retinoblastoma cell lines. Tumor laterality (bi: bilateral, uni: unilateral) and patient age at diagnosis are given. Genomic coordinates of RB1 mutations detected by sequencing refer to Genbank accession number NC_000013.10. RB1 copy number was assessed by MLPA: 0: no allele present, 0.5: one copy, 1: two copies, 1.5: three copies. Number of parentally different chromosomes 13 (chr13 zygosity) was determined by microsatellite analysis. MYCN amplification status determined by DNA FISH: gain: ratio MYCN/control between 1.5 and 4, amplification: ratio > 4.
induction of retinoblastoma and that amplification of MYCN alone can result in tumor formation [35, 48] . The MYCN amplification status was determined in all ten retinoblastoma cell lines by DNA FISH-analysis ( Supplementary Fig. 2 , Table 1 ). No aberration (1-fold) of MYCN was observed in the cell lines RBL13 and RBL15. Cell lines RBL30, RB247C3 and WERI-Rb1 showed a gain of MYCN (1.5-4-fold). MYCN amplification (> 4-fold) was detected in cell lines RB355, RB383, RB522, RB3823 and Y79 (Supplementary Fig. 1 ; Table 1 ). These results refine the data about MYCN amplification in retinoblastoma cell lines reported by others [13, 20, 35, 41] Retinoblastoma is known to harbor additional genomic aberrations, like gain of 1q or 6p and loss of 16q [9] [10] [11] . To test if the cell lines carry any of these chromosomal aberrations, copy number variation was analyzed by SNP arrays (Supplementary table 3) . Gain of chromosome 1q and gain of chromosome 2p was observed in all cell lines. The gain on chromosome 2p in cell lines RBL13 and RBL15 did not include the MYCN gene. Gain of chromosome 6p was observed in all cell lines except RB522, RB3823 and WERI-Rb1. Loss of 16q was detected in cell lines RBL13, RBL15, RB247C3, RB383, WERI-Rb1 and Y79. Cell line RBL13 carried the most (27) CNVs, RB3823 the least (3). Chromosomes 1, 2 and 18 were aberrant most often. Exome sequencing of tumor samples revealed a low number of recurrent mutations [16, 50] . To assess the situation in retinoblastoma cell lines, which could carry additional germline or tumor-derived mutations or might have acquired additional changes during cultivation, targeted sequencing of 160 candidate genes often mutated in cancer was performed. However, using the filter criteria of at least 50 reads per region only about half of the regions covering these 160 genes could be analyzed. RB1 mutations were detected in cell lines RB247C3, RB355 and Y79 ( Table 2 ). The deletion of RB1 in cell lines RBL15 and WERI-Rb1 was represented by the complete absence of reads across all 26 RB1 amplicons included in the panel. RB1 exons harboring mutations in cell lines RBL13 (exon 10), RBL30 (exon 8) and RB355 (exon 22) were not called as they did not reach a coverage of 50 reads. Additional variants were identified in 13 cancer-associated genes. Mutations in the TP53 tumor suppressor gene or BCOR, which has been reported as second most frequently mutated gene in retinoblastoma [26, 50] could not be analyzed due to low coverage. None of the variants were recurrent. Of 18 different variants observed, eight were missense, three in frame deletions, three frameshift, one synonymous, one nonsense and one splice region variants. Four of the missense variants and the in frame deletion in ZNF2 were polymorphisms. By PolyPhen-2, two of the four remaining missense variants were predicted to be probably damaging and two to be benign. WERI-Rb1 and RB522 cells both showed mutations in the APC gene ( (Fig. 2) . The levels of transcripts varied between cell lines. As expected, RB1 protein was absent in all cell lines analyzed, with exception of RB522 and RB3823 (RB1 wt /MYCN A ) ( Fig. 2A) . MYCN expression was analyzed in our retinoblastoma cell line panel and in two neuroblastoma cell lines, SHEP (no MYCN amplification) and WAC2 (ectopic overexpression of MYCN, [38] ). All ten retinoblastoma cell lines showed expression of MYCN on mRNA and protein level (Fig. 2B) . Relative to the neuroblastoma cell line SHEP, MYCN mRNA expression is notably increased in all retinoblastoma cell lines, except RB247C3. On average, MYCN expression was about 12-fold higher (p = 0.02) in MYCN amplified than in non-amplified retinoblastoma cell lines. On average, protein expression levels of MYCN mirrored mRNA expression results, except for cell line RB355 (Fig. 2B) . Retinoblastoma tumors are presumed to originate from cone precursor cells in the retina and have been shown to express genes characteristic for photoreceptors and other retina-specific genes [17, 49] . We tested for expression of CRX, RXRG and RCVRN, marker genes expressed in immature and mature photoreceptors. CRX was similarly Fig. 1 . Analysis of DNA methylation at CpG106 (RB1 promoter). DNA methylation was measured quantitatively by next-generation bisulfite amplicon sequencing. CpG106 was unmethylated in all cell lines, except RB383. Individual reads are in lines, single CpG sites are in columns, blue: not methylated, red: methylated. Read numbers and overall percentage of methylation are given below the plots. (Fig. 3A) . On the contrary, expression of RXRG was highly upregulated in all the three subgroups. TP53 is a tumor suppressor mutated in a substantial number of tumors, but usually not in retinoblastoma [27] . It is assumed that high expression of TP53 negative regulators MDM2 and MDM4, bypasses the active TP53 signaling pathway in retinoblastoma. In all retinoblastoma cell lines, TP53 expression was moderately upregulated compared to healthy fibroblast cells (NHDF) (Fig. 3B) Expression of MDM2 was comparable to expression measured in NHDF, but mRNA expression of MDM4 was highly upregulated in all cell lines in all three groups. No significant differences in expression levels of MDM2 and MDM4 were observed between the three groups of retinoblastoma cell lines. RB1 and MYCN exhibit negative and positive functions in the control of cell cycle progression, respectively. Loss of RB1 and amplification of MYCN in retinoblastoma is therefore thought to alter expression and function of cell cycle relevant genes and proteins. In the retinoblastoma cell lines, we measured mRNA expression levels of cyclindependent kinases, CDK4 and CDK1, as well as of the E2F transcription factors, E2F1 and E2F3 (Fig. 3C) . CDK4 was expressed at comparable level to the fibroblast cell line NHDF. Expression of CDK1, E2F1 and E2F3 was upregulated in all three groups of retinoblastoma cell lines. However, variation was high in three independent biological measurements and between cell lines in the groups. Differences in mean expression of CDK1 are therefore not statistically significant. E2F1 and E2F3 expression is uniformly elevated in all three groups.
Discussion
Because of a lack of adequate animal models and low amount of available tumor material, in vitro models for retinoblastoma tumorigenesis are of crucial importance to investigate, develop and improve therapy options. Here, thorough characterization and identification by microsatellite profiling of ten retinoblastoma cell lines is provided, which is mandatory for model development. Sequencing, MLPA, microsatellite and DNA methylation analyses confirmed the RB1 mutations already described for cell lines RBL13, RBL15, RBL30, Y79 and WERI-Rb1 and enabled, to our knowledge for the first time, exact description of the RB1 inactivating mechanism in cell lines RB355, RB247C3 and RB383 (Table 1 ). In cell line RB383 mutations in RB1 were absent, but hypermethylation of the RB1 promoter on all alleles was identified by next-generation bisulfite amplicon sequencing (Fig. 1) . MLPA analysis indicated the presence of three copies of chromosome 13 in cell line RB383. DNA FISH analysis, using hybridization to chromosome 21 and 13, revealed that cell line RB383 is overall tetraploid (four signals for chromosome 21) and even hexaploid for chromosome 13 (six signals; Supplementary Fig. 2 ). This analysis also included cell lines RB522 and RB3823, which were derived from retinoblastoma tested negative for RB1 mutations but showing amplification of the MYCN gene ( [35] , personal communication Brenda Gallie, Toronto, Canada). These results were confirmed and expression of RB1 was demonstrated in these cell lines (Fig. 2A) . All other retinoblastoma cell lines showed absence of RB1 protein expression. This set of ten retinoblastoma lines therefore represents and includes cell lines covering all possible causes of retinoblastoma tumorigenesis described so far: (1) point mutations in RB1 (RBL30); (2) loss of the entire RB1 gene with LOH (RBL15, WERI-Rb1) (3) different small mutations on both alleles of RB1, including splice site mutations (RBL13, RB247C3, RB355, Y79); (4) RB1 promoter hypermethylation (RB383); and (5) MYCN amplification (RB522, RB3823).
Besides genetic aberrations in RB1 or MYCN, retinoblastoma is a tumor with only few additional genetic aberrations [17] . In general, the mutation profile of cancer associated genes will be helpful to understand the response of individual cell lines to therapeutics, for example mTOR inhibitors that are tested in in vitro preclinical model systems [45] . Targeted sequencing of the retinoblastoma cell lines revealed only few variants in other cancer predisposing genes (Table 2) , indicating relative genomic stability even in prolonged in vitro culture. It is possible that these mutations were already present in the primary retinoblastoma. However, a strong and profound analysis of the cancer panel targeted sequencing was hampered by low performance of the panel. Aiming at a minimum read number of 50, only 30-70% of included regions could be analyzed.
Formation of retinoblastoma depends on high-level expression of the oncogenic driver MYCN. This is underlined by identification of rare retinoblastoma entities exhibiting wildtype RB1 but amplification of MYCN [35] . It has been impressively demonstrated that the specific expression pattern of high MYCN, MDM2 and RXRG in postmitotic cone precursor cells in the retina renders this cell type especially sensitive to RB1 loss [48, 49] . This explains the almost exclusive restriction of RB1-negative tumors to the retina. Overexpression of human MYCN in an Rb1-mutant mouse model resulted in development of retinoblastoma with full penetrance, highlighting the synergy and dependency of this tumor on elevated MYCN expression [47] . Increased expression of MYCN was present in all ten retinoblastoma cell lines, independent of genetic MYCN amplification (Fig. 2B, Table 1 [14, 25] . Compared to healthy human retina, CRX expression was normal but RXRG was elevated in all retinoblastoma cell lines (Fig. 3A) . In contrast, expression of RCVRN, a marker for mature photoreceptor cells, was low, underlining the undifferentiated status of retinoblastoma cell lines. As discussed, photoreceptor precursor cells in the human retina are especially susceptible to loss of RB1, because their specific gene expression circuitry with high expression of MDM2, MYCN and RXRG [49] . MDM2 targets TP53 for degradation and high levels of MDM2, or its homolog MDM4, can bypass the induction of apoptosis by TP53 signaling in cells with RB1 loss [19] . In contrast to many other types of cancer, mutations in TP53 are absent in retinoblastoma, but amplification of the MDM4 and MDM2 genes has been described in 75% of retinoblastoma [19] . Mutations in TP53 were not detected in ten cell lines (Table 2) , gene expression of MDM2 was normal but MDM4 was upregulated in all cell lines regardless of RB1 or MYCN status (Fig. 3B) . Expression of TP53 itself was elevated in all cell lines showing the least upregulation in RB3823 and RB522, the cell lines with intact RB1 but MYCN amplification (RB1 wt / MYCN A ). The observed differences in expression were significant between the group RB1 mut /MYCN nonA and both MYCN A groups. Aberrations in MYCN and RB1 contribute to deregulation of the cell cycle in tumor cells. MYCN promotes cell cycle transition and as a transcription factor it directly regulates genes such as CDK1 [33] , E2F1 and E2F3 [23] as well as MDM2 [40] and TP53 [6, 40] . Based on elevated expression of MYCN in retinoblastoma cell lines we expected expression levels of E2F1, E2F3, CDK1 and TP53 to be elevated in retinoblastoma cell lines, which was indeed observed (Fig. 3B, C) . However, expression levels were comparable between the three groups and not directly related to RB1 loss or MYCN amplification. The presented results on ten established retinoblastoma cell lines supplement existing data and provide new information on genetic characteristics and will facilitate the choice of the appropriate cell lines for experiments and the interpretation of in vitro data. This enables even more precise studies on the tumor biology of retinoblastoma. Cellular pathways in different conditions can be analyzed and differences in sensitivity to chemotherapeutic drugs depending on the underlying genetic or epigenetic cause can be tested.
